SE0300831D0 - New formulations and use therof - Google Patents

New formulations and use therof

Info

Publication number
SE0300831D0
SE0300831D0 SE0300831A SE0300831A SE0300831D0 SE 0300831 D0 SE0300831 D0 SE 0300831D0 SE 0300831 A SE0300831 A SE 0300831A SE 0300831 A SE0300831 A SE 0300831A SE 0300831 D0 SE0300831 D0 SE 0300831D0
Authority
SE
Sweden
Prior art keywords
new formulations
use therof
formulation
therof
apis
Prior art date
Application number
SE0300831A
Other languages
English (en)
Swedish (sv)
Inventor
Fredrik Nicklasson
Kristina Thyresson
Nils-Olof Lindberg
Alice C Martino
Kristina Lindell
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE0300831A priority Critical patent/SE0300831D0/xx
Publication of SE0300831D0 publication Critical patent/SE0300831D0/xx
Priority to BRPI0408655-4A priority patent/BRPI0408655A/pt
Priority to PCT/IB2004/000860 priority patent/WO2004084865A1/en
Priority to MXPA05010196A priority patent/MXPA05010196A/es
Priority to CA002519155A priority patent/CA2519155A1/en
Priority to EP04720946A priority patent/EP1605921A1/en
Priority to AU2004224557A priority patent/AU2004224557B2/en
Priority to JP2006506377A priority patent/JP2006521348A/ja
Priority to CNA2004800077898A priority patent/CN1764440A/zh
Priority to CL200400564A priority patent/CL2004000564A1/es
Priority to TW093107802A priority patent/TW200503782A/zh
Priority to ARP040100981A priority patent/AR043772A1/es
Priority to US10/816,672 priority patent/US20040191298A1/en
Priority to ZA200507719A priority patent/ZA200507719B/en
Priority to US12/143,001 priority patent/US20080249143A1/en
Priority to US12/709,953 priority patent/US20100197742A1/en
Priority to JP2010255113A priority patent/JP2011079841A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
SE0300831A 2003-03-26 2003-03-26 New formulations and use therof SE0300831D0 (sv)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE0300831A SE0300831D0 (sv) 2003-03-26 2003-03-26 New formulations and use therof
PCT/IB2004/000860 WO2004084865A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
AU2004224557A AU2004224557B2 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
CNA2004800077898A CN1764440A (zh) 2003-03-26 2004-03-16 包含活性成分和可可粉的制剂及其用途
MXPA05010196A MXPA05010196A (es) 2003-03-26 2004-03-16 Nuevas formulaciones y su uso.
CA002519155A CA2519155A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
EP04720946A EP1605921A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
BRPI0408655-4A BRPI0408655A (pt) 2003-03-26 2004-03-16 formulações compreendendo um agente ativo e cacau em pó e a sua utilização
JP2006506377A JP2006521348A (ja) 2003-03-26 2004-03-16 活性成分及びカカオ粉末を含む製剤、並びにその使用
CL200400564A CL2004000564A1 (es) 2003-03-26 2004-03-18 Formulacion farmaceutica para administracion oral que comprende uno o mas agentes farmaceuticamente activos y cacao en polvo.
TW093107802A TW200503782A (en) 2003-03-26 2004-03-23 New formulations and use thereof
ARP040100981A AR043772A1 (es) 2003-03-26 2004-03-24 Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso
US10/816,672 US20040191298A1 (en) 2003-03-26 2004-04-02 New formulations and use thereof
ZA200507719A ZA200507719B (en) 2003-03-26 2005-09-23 Formulations comprising an active ingredient and cocoa powder and use thereof
US12/143,001 US20080249143A1 (en) 2003-03-26 2008-06-20 New formulations and use thereof
US12/709,953 US20100197742A1 (en) 2003-03-26 2010-02-22 New formulations and use thereof
JP2010255113A JP2011079841A (ja) 2003-03-26 2010-11-15 活性成分及びカカオ粉末を含む製剤、並びにその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300831A SE0300831D0 (sv) 2003-03-26 2003-03-26 New formulations and use therof

Publications (1)

Publication Number Publication Date
SE0300831D0 true SE0300831D0 (sv) 2003-03-26

Family

ID=20290786

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300831A SE0300831D0 (sv) 2003-03-26 2003-03-26 New formulations and use therof

Country Status (13)

Country Link
EP (1) EP1605921A1 (xx)
JP (2) JP2006521348A (xx)
CN (1) CN1764440A (xx)
AR (1) AR043772A1 (xx)
AU (1) AU2004224557B2 (xx)
BR (1) BRPI0408655A (xx)
CA (1) CA2519155A1 (xx)
CL (1) CL2004000564A1 (xx)
MX (1) MXPA05010196A (xx)
SE (1) SE0300831D0 (xx)
TW (1) TW200503782A (xx)
WO (1) WO2004084865A1 (xx)
ZA (1) ZA200507719B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA02004293A (es) 1999-10-29 2002-10-31 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada..
EP1337244A4 (en) 2000-10-30 2006-01-11 Euro Celtique Sa HYDROCODON FORMULATIONS WITH CONTROLLED RELEASE
JP5558712B2 (ja) * 2005-08-02 2014-07-23 ドロサファーム アクチェンゲゼルシャフト インドメタシン及び／又はアセメタシンを含む医薬組成物
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
AU2008262870B2 (en) 2007-06-13 2013-07-11 Otsuka Pharmaceutical Co., Ltd. Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food
CN101444273B (zh) * 2007-11-22 2013-04-24 何煜 一种保健品口腔速释制剂及其制造方法
CN101439053A (zh) * 2007-11-22 2009-05-27 何煜 一种中药口腔速释制剂及其制造方法
WO2009070978A1 (fr) * 2007-11-22 2009-06-11 Yu He Libération rapide dans la cavité buccale des produits de santé et procédé de préparation associé
JP2012527406A (ja) * 2009-05-20 2012-11-08 リングアル コンセグナ ピーティーワイ エルティーディー 口腔内および／または舌下治療用製剤
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
US20160000714A1 (en) 2013-03-06 2016-01-07 Capsugel Belgium Nv Curcumin solid lipid particles and methods for their preparation and use
CN103583781B (zh) * 2013-11-01 2015-11-25 阳波 咖啡味甲硝唑口香糖
US20170112762A1 (en) * 2014-06-10 2017-04-27 Capsugel Belgium Nv Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
US11324699B2 (en) 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
JP6334482B2 (ja) * 2015-08-28 2018-05-30 中野Ｂｃ株式会社 固形剤とその製造方法
CN108135869A (zh) * 2015-12-09 2018-06-08 波维瓦茶业有限责任公司 包含亲脂性活性剂的口服可消化组合物的配制方法
AU2016367037B2 (en) * 2015-12-09 2019-05-02 Poviva Corp. Stable ready-to-drink beverage compositions comprising lipophilic active agents
EP3541393A4 (en) 2016-11-18 2020-06-17 The University Of Western Australia TASTE MASKING PRODUCT
EP3758675A1 (de) * 2018-03-01 2021-01-06 LTS Lohmann Therapie-Systeme AG Orale darreichungsform mit theobrominfreiem kakao
CN109053718B (zh) * 2018-08-09 2022-06-03 天津理工大学 一种罗格列酮糖精盐及其制备方法
CN111729087A (zh) * 2020-07-24 2020-10-02 成都大学 一种选择性β2受体激动剂的脂质修饰物及其制备方法与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785574A (en) * 1955-03-29 1957-10-30 Pfizer & Co C Pharmaceutical compositions containing tetracycline antibiotics
GB918955A (en) * 1960-05-19 1963-02-20 Thomae Gmbh Dr K Pharmaceutical laxative compositions comprising 4,4-dihydroxy-2-amino triphenylmethane
FR2717387B1 (fr) * 1994-03-17 1996-10-18 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
SE9803986D0 (sv) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
JP2001106641A (ja) * 1999-10-06 2001-04-17 Tendou Seiyaku Kk 口内薬
JP2001114668A (ja) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd チョコレート剤
JP2002193839A (ja) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd ココア製剤
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
SE0103211D0 (sv) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof

Also Published As

Publication number Publication date
CL2004000564A1 (es) 2005-02-04
EP1605921A1 (en) 2005-12-21
CA2519155A1 (en) 2004-10-07
AU2004224557A1 (en) 2004-10-07
TW200503782A (en) 2005-02-01
WO2004084865A1 (en) 2004-10-07
JP2006521348A (ja) 2006-09-21
AR043772A1 (es) 2005-08-10
MXPA05010196A (es) 2005-11-08
BRPI0408655A (pt) 2006-03-28
AU2004224557B2 (en) 2009-06-18
JP2011079841A (ja) 2011-04-21
ZA200507719B (en) 2007-09-26
CN1764440A (zh) 2006-04-26

Similar Documents

Publication Publication Date Title
SE0300831D0 (sv) New formulations and use therof
WO2004112711A3 (en) Oral extended-release composition
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
HUP0203168A2 (hu) Készítmények nyálkahártyán át történő beadásra
MY143795A (en) Tetrahydropyridoindole derivatives
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
HUP0301349A2 (hu) IL-11-tartalmú készítmények
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
BG108516A (en) Pharmaceutical formulation
AU2357202A (en) Ion-strength independent sustained release pharmaceutical formulation
NO331082B1 (no) Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
SE0001916D0 (sv) Novel formulation
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
HUP0500642A2 (hu) Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
SE0103210D0 (sv) New formulations and use thereof
WO2004052331A3 (fr) Utilisation d'un extrait de miellat de coton comme ingredient acitif
SE0300830D0 (sv) New formulations and use thereof
AU2003285125A8 (en) Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
ECSP045056A (es) Composiciones de valdecoxib de disgregación intraoral preparadas mediante un procedimiento de desecación por pulverizacion